carbamates has been researched along with Electrocardiogram QT Prolonged in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Encorafenib (Braftovi) is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation, in combination with binimetinib (Mektovi)." | 4.02 | Relatively mild symptoms after chronic overdose with a double-dose encorafenib: a case report. ( Lankheet, NAG; Meussen, E; Mian, P; Piersma, D, 2021) |
| " Maintenance dosing was for 9 days." | 2.76 | QT response after a test dose and during maintenance therapy with AZD1305 in patients with atrial fibrillation: a double-blind, randomized, placebo-controlled trial. ( Aunes-Jansson, M; Bergfeldt, L; Berggren, A; Duris, T; Edvardsson, N; Egstrup, K; Frison, L; Gullestad, L; Johansson, S; Kochmanski, M; Kuśnierz, B; Nielsen, T; Sawicki, S, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Darpo, B | 2 |
| Sager, PT | 1 |
| Xue, H | 2 |
| Kamin, M | 1 |
| Borin, MT | 1 |
| Barnes, CN | 1 |
| Pendyala, S | 1 |
| Bourdet, DL | 1 |
| Zomorodi, K | 1 |
| Chen, D | 1 |
| Lee, L | 1 |
| Swearingen, D | 1 |
| Carter, LP | 1 |
| Mian, P | 1 |
| Meussen, E | 1 |
| Piersma, D | 1 |
| Lankheet, NAG | 1 |
| Bergenholm, L | 1 |
| Parkinson, J | 1 |
| Mettetal, J | 1 |
| Evans, ND | 1 |
| Chappell, MJ | 1 |
| Collins, T | 1 |
| Rivera-Arconada, I | 1 |
| Vicente-Baz, J | 1 |
| Lopez-Garcia, JA | 1 |
| Maljevic, S | 1 |
| Wuttke, TV | 1 |
| Seebohm, G | 1 |
| Lerche, H | 1 |
| Egstrup, K | 1 |
| Bergfeldt, L | 1 |
| Duris, T | 1 |
| Gullestad, L | 1 |
| Kochmanski, M | 1 |
| Kuśnierz, B | 1 |
| Nielsen, T | 1 |
| Sawicki, S | 1 |
| Aunes-Jansson, M | 1 |
| Edvardsson, N | 1 |
| Frison, L | 1 |
| Johansson, S | 1 |
| Berggren, A | 1 |
| Inglis, F | 1 |
| Preskorn, SH | 1 |
| Borges-Gonzalez, S | 1 |
| Flockhart, D | 1 |
| Walsh, E | 1 |
| Dourish, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Placebo-controlled, Double-blind, Parallel-group, Multicentre, Phase IIa Study to Explore the Relationship Between QTcF Interval at First Dose (Loading Dose) and at Steady State After Treatment With AZD1305 Extended-release Tablets or Placeb[NCT00643448] | Phase 2 | 65 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients who had at least one AE according to the definition in the study protocol (NCT00643448)
Timeframe: During treatment days 2-10
| Intervention | Participants (Number) |
|---|---|
| AZD1305 Group A and AZD1305 Group B | 22 |
| Placebo | 13 |
Percentage of twice daily TTM recordings (individual compliance) transmitted and available for analysis (NCT00643448)
Timeframe: During treatment days 1-10
| Intervention | Percentage of recordings analysed (Mean) |
|---|---|
| AZD1305 Group A | 97.4 |
| AZD1305 Group B | 96.4 |
| Placebo | 98.3 |
Population PK model parameter estimates derived from plasma concentrations of AZD1305 (NCT00643448)
Timeframe: During treatment days 1-10
| Intervention | μmol/L (Mean) |
|---|---|
| AZD1305 Group A | 0.41 |
| AZD1305 Group B | 0.45 |
Maximum of all QTcF values obtained for any given patient from randomisation until the intended end of the study drug period, day 10. (NCT00643448)
Timeframe: During treatment days 2-10
| Intervention | ms (Mean) |
|---|---|
| AZD1305 Group A and AZD1305 Group B | 461 |
| Placebo | 427 |
2 reviews available for carbamates and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
KV7 channelopathies.
Topics: Animals; Carbamates; Channelopathies; Epilepsy; Humans; KCNQ Potassium Channels; Long QT Syndrome; M | 2010 |
Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II.
Topics: Anti-HIV Agents; Antidepressive Agents; Antiparkinson Agents; Apomorphine; Atazanavir Sulfate; Azabi | 2006 |
5 trials available for carbamates and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
A Phase 1 Clinical Study Evaluating the Effects of Cenobamate on the QT Interval.
Topics: Adult; Carbamates; Chlorophenols; Double-Blind Method; Humans; Long QT Syndrome; Tetrazoles | 2022 |
Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study.
Topics: Adolescent; Adult; Benzamides; Carbamates; Cross-Over Studies; Double-Blind Method; Electrocardiogra | 2020 |
A Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants.
Topics: Adrenergic Uptake Inhibitors; Adult; Carbamates; Cross-Over Studies; Dopamine Uptake Inhibitors; Dos | 2021 |
Predicting QRS and PR interval prolongations in humans using nonclinical data.
Topics: Animals; Anti-Arrhythmia Agents; Azabicyclo Compounds; Carbamates; Dogs; Drug Evaluation, Preclinica | 2017 |
QT response after a test dose and during maintenance therapy with AZD1305 in patients with atrial fibrillation: a double-blind, randomized, placebo-controlled trial.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Azabicyclo Compounds; Carbamates; Delayed-Action | 2011 |
4 other studies available for carbamates and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Relatively mild symptoms after chronic overdose with a double-dose encorafenib: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; C | 2021 |
Targeting Kv7 channels in pain pathways.
Topics: Aminopyridines; Animals; Carbamates; Deafness; Epilepsy; Humans; Inflammation; KCNQ Potassium Channe | 2017 |
Rivastigmine and QT interval prolongation.
Topics: Carbamates; Cholinesterase Inhibitors; Humans; Long QT Syndrome; Neuroprotective Agents; Phenylcarba | 2003 |
Prolonged QT interval with rivastigmine.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Long QT Syndrome; Male; Neur | 2002 |